Medicaments containing gelatin cross-linked with oxidized polysa

Details Medicaments containing gelatin cross-linked with oxidized polysa Medicaments containing gelatin cross-linked with oxidized polysa

1998-10-27

2000-10-17

Kulkosky, Peter F.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Web, sheet or filament bases; compositions of bandages; or...

424449, 424488, 424499, A61L 1532, A61K 950

Patent

active

06132759&

DESCRIPTION:

BRIEF SUMMARY
The present invention relates to a medicament containing a biopolymer matrix comprising gelatin cross linked with oxidized polysaccharides. The material is useful for the covering of a variety of wound types, particularly chronic wounds and burns. The material is also suitable for the controlled release of drugs. When loaded with suitable growth factors or wound repair promoting substances, the matrix is useful for the fabrication of wound dressings for the treatment of a variety of wound types, particularly chronic wounds and burns.
A very large number of people are suffering from chronic non-healing skin wounds. Worldwide, 8 million people have chronic leg ulcers and 7 million people have pressure sores (Clinica 559, 14-17, 1993). In the US alone, the prevalence of skin ulcers is 4.5 million, including 2 million pressure sore patients, 900,000 venous ulcer patients and 1.6 million diabetic ulcer patients (Med Pro Month, June 1992, 91-94). The cost involved in treating these wounds is staggering and, at an average of $3,000 per patient, reaches over $13 billion per year for the US alone. Burn wounds have a reported incidence of 7.8 million cases per year worldwide, 0.8 million of which need hospitalisation (Clinica 559). In the US there are 2.5 million burn patients per year, 100,000 of which need hospitalization and 20,000 of which have burns involving more than 20% of the total body surface area (MedPro Month, June 1992).
A common feature in the treatment of these wounds is that they need covering for optimal healing. The beneficial effect of covering wounds is situated at different levels and is dependent on the type of dressing material used. First, especially with acute wounds, suitable dressings may help to achieve haemostasis and thus control blood loss. Secondly, covering effectively shields the wound from the environment, thus protecting it from microbial contamination. Furthermore, some so-called occlusive or semi-occlusive wound dressings have the capability of maintaining the wound moist, which is beneficial for healing. Finally, some wound dressings may themselves directly promote the healing process, for instance because they contain components which directly promote cell growth or migration or which attract or activate cells from the immune system which on their turn secrete growth-promoting substances. Other dressings may contain antimicrobial substances, which are helpful to control infection of the wound.
Over time, a surprisingly wide variety of dressing materials have been used for wound covering, many of which are currently commercially available. Each of them has its own indications, dependent on wound type, depth, size, absence or presence of infection, level of exudate formation, etc.
Cotton gauze, for instance, is widely used as wound dressing. It has the advantage of being cheap, but the disadvantage of being not occlusive and sometimes becoming encrusted into the wound. To prevent this, these dressings are sometimes impregnated with a greasy substance, such as paraffin. A commercially available example of such a dressing is Jelonet.TM. (Smith and Nephew, UK).
Another class of wound dressings are the absorptive hydrogel dressings. These have no occlusive properties, but have a high capacity for the absorption of exudate and slough. They consist of hydrophilic polymers such as gelatin, polysaccharides, polyacrylamide, etc. which swell upon contact with wound fluid and can absorb several times their own weight of exudate. Commercially available hydrogel dressings include Intrasite gel (Smith and Nephew, UK) and Vigilon (CR Bard, USA). A special type of hydrogels are the alginates, which are hydrophilic polysaccharides extracted from seaweed. They are produced as thin non-woven tissues or as ropes. Upon contact with the wound fluid, they turn into a gel which has a high absorptive capacity for wound fluid. Examples include Kaltostat (Brit-Cair, UK) and Sorbsan (Steriseal, UK).
Another type of dressings are the occlusive or semi-occlusive dressings. In their simplest form, they usual

REFERENCES:
patent: 5041292 (1991-08-01), Feijen et al.
patent: 5676967 (1997-10-01), Williams et al.
patent: 5783214 (1998-07-01), Royer

Affiliated with

Also associated with

Rating

Medicaments containing gelatin cross-linked with oxidized polysa does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicaments containing gelatin cross-linked with oxidized polysa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicaments containing gelatin cross-linked with oxidized polysa will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-465919